DNA damage in IDH-mutant gliomas: mechanisms and clinical implications

[1]  R. Deberardinis,et al.  De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma , 2022, Cancer cell.

[2]  R. Koche,et al.  Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting tumor mutation burden , 2022, bioRxiv.

[3]  Christine C. Hudson,et al.  Mutant-IDH inhibits Interferon-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. , 2021, Cancer discovery.

[4]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[5]  S. Heiland,et al.  Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas , 2021, Nature Cancer.

[6]  D. Maucort-Boulch,et al.  Olaparib in recurrent IDH-mutant high-grade glioma (OLAGLI). , 2021 .

[7]  W. Mason,et al.  Combination olaparib and durvalumab for patients with recurrent IDH-mutated gliomas. , 2021 .

[8]  K. Aldape,et al.  Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. , 2021, The Lancet. Oncology.

[9]  M. Snuderl,et al.  Molecular Signatures of Chromosomal Instability Correlate With Copy Number Variation Patterns and Patient Outcome in IDH-Mutant and IDH-Wildtype Astrocytomas. , 2021, Journal of neuropathology and experimental neurology.

[10]  T. Jiang,et al.  Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma , 2021, Cancer biology & medicine.

[11]  Jennie W. Taylor,et al.  Abstract 2046: Inhibiting IDH mutations in low-grade glioma alters cellular function and the immune environment , 2020 .

[12]  H. Wakimoto,et al.  Poly(ADP-ribose) glycohydrolase inhibition sequesters NAD+ to potentiate the metabolic lethality of alkylating chemotherapy in IDH mutant tumor cells. , 2020, Cancer discovery.

[13]  J. Shay,et al.  Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity. , 2020, Cancer cell.

[14]  P. Glazer,et al.  Oncometabolites suppress DNA repair by disrupting local chromatin signalling , 2020, Nature.

[15]  E. Maher,et al.  INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation. , 2020 .

[16]  B. Shuch,et al.  Oncometabolites suppress DNA repair by disrupting local chromatin signaling , 2020, Nature.

[17]  J. Huse,et al.  Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas , 2020, Science Advances.

[18]  Raymond Y Huang,et al.  Mechanisms and therapeutic implications of hypermutation in gliomas , 2020, Nature.

[19]  T. Richardson,et al.  Total copy number variation, somatic mutation burden, and histologic grade correlate with clinical outcome in oligodendroglioma. , 2020, Clinical neuropathology.

[20]  M. Snuderl,et al.  Total copy number variation as a prognostic factor in adult astrocytoma subtypes , 2019, Acta Neuropathologica Communications.

[21]  Christian M. Metallo,et al.  Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma , 2018, Cell.

[22]  M. Weller,et al.  Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate , 2018, Nature Medicine.

[23]  C. Marosi,et al.  Correlation of immune phenotype with IDH mutation in diffuse glioma , 2017, Neuro-oncology.

[24]  A. Iafrate,et al.  The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity. , 2017, Cancer research.

[25]  A. M. Houghton,et al.  Mutant IDH1 regulates the tumor-associated immune system in gliomas , 2017, Genes & development.

[26]  J. Costello,et al.  Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas , 2017, The Journal of clinical investigation.

[27]  M. Gilbert,et al.  Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair. , 2017, Cancer research.

[28]  Gregory A. Breuer,et al.  2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity , 2017, Science Translational Medicine.

[29]  C. Perou,et al.  Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. , 2015, Cell reports.

[30]  A. Iafrate,et al.  Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. , 2015, Cancer cell.

[31]  Shawn M. Gillespie,et al.  Insulator dysfunction and oncogene activation in IDH mutant gliomas , 2015, Nature.

[32]  W. Vandertop,et al.  Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. , 2015, Cancer research.

[33]  Susan M. Chang,et al.  Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment , 2015, Acta Neuropathologica.

[34]  Jing Chen,et al.  Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation , 2015, Tumor Biology.

[35]  Caterina Giannini,et al.  Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Steven J. M. Jones,et al.  Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.

[37]  W. Kaelin,et al.  What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. , 2013, Genes & development.

[38]  Benjamin L. Ebert,et al.  (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible , 2013, Science.

[39]  S. Mulholland,et al.  MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations , 2012, International journal of cancer.

[40]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[41]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[42]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[43]  Magnar Bjørås,et al.  Human and bacterial oxidative demethylases repair alkylation damage in both RNA and DNA , 2003, Nature.

[44]  P. Bates,et al.  Reversal of DNA alkylation damage by two human dioxygenases , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[45]  S. Shibata,et al.  Protective Role of Glutathione Synthesis on Radiation-Induced DNA Damage in Rabbit Brain , 1998, Cellular and Molecular Neurobiology.

[46]  A. Meister.  Glutathione, ascorbate, and cellular protection. , 1994, Cancer research.

[47]  Cairncross,et al.  CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design , 2021 .

[48]  Zachary,et al.  Oncometabolites Dand L-2-hydroxyglutarate Inhibit the AlkB Family DNA Repair Enzymes under Physiological Conditions , 2017 .

[49]  J. Uhm.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .

[50]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2010, Nature.

[51]  Zhao,et al.  IDH 1R 132 H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response , 2022 .